LONDON - Bioniq, an AI-driven personalized supplement company, has secured $15 million in Series B funding to advance its international expansion and product development. The funding round, led by HV Capital and Unbound, two prominent European venture capital firms, values the London-based startup at $75 million.
Founded in 2019, Bioniq has distinguished itself in the dietary supplements market by offering tailor-made solutions based on individual blood biomarker data. The company's growth has been particularly strong in the U.S., which now represents over half of its customer base. Notably, demand in some U.S. regions has surged by more than 500% in the last two quarters.
The new capital will be directed towards expanding Bioniq's global laboratory network, increasing market presence, and scaling operations and human resources, particularly in the U.S. and Middle East. Additionally, a corporate platform for medical, wellness, and athletic institutions will be implemented.
Bioniq's personalized approach has earned the endorsement of top athletes and partnerships with health institutions, leveraging its AI technology and extensive biochemical database to create customized supplements. The company offers two main products: Bioniq PRO, which includes blood biomarker analysis for detailed nutrient optimization, and Bioniq GO, an accessible option utilizing a questionnaire to recommend tailored supplement blends.
All of Bioniq's products are Swiss-made and pharmaceutical-grade, featuring a unique mix of nutrients delivered in patented prebiotic guar granules to maximize bioavailability. The company's approach has been recognized for setting a new industry standard by providing transparent processes and results to users.
The Series B funding announcement underscores Bioniq's position as a leader in the personalized nutrition space and reflects investor confidence in its potential to reshape the supplement industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.